Table 2.
Characteristics of studies investigating the effects of low-dose BCG
| First author, yr | Design, LOE | No. of Case/Control | Age Case/Control* | Disease category | Follow-up, mo Case/Control* | Strain | Treatment dose (mg) Case/Control | Maintenance** Case/Control |
|---|---|---|---|---|---|---|---|---|
| Ojea 2007 [25] |
RCT, 1b |
139/142 |
64.9/65.1 |
Intermediate-Risk NMIBC |
61.2/57.3 |
Connaught |
13.5/27 |
Yes/Yes |
| Yalcinkaya 1998 [7] |
RCT, 1b |
25/25 |
56.3/55.3 |
Superficial BCa |
26.8/31.6 |
Connaught |
54/81 |
No/No |
| Kumar 2002 [6] |
RCT, 2b |
13/13 |
55.9/56.7 |
NMIBC without CIS |
24(12–30) |
Danish 1331 |
40/120 |
No/No |
| Oddens 2013 [28] |
RCT, 1b |
678/677 |
68.0/67.0 |
Intermediate and high risk NMIBC |
85.2 |
OncoTice |
27/81 |
Yes/Yes |
| Takashi 1995 [27] |
R, 2b |
37/37 |
68.1/61.4 |
Superficial BCa |
32 |
Tokyo 172 |
40/80 |
No/No |
| Yoneyama 2008 [5] |
R, 2b |
65/85 |
68.3/65.5 |
NMIBC without CIS |
42.2/90.7 |
Tokyo 172 |
40/80 |
No/No |
| Irie 2003 [26] | R, 2b | 41/39 | 61.6/62.2 | Superficial BCa | 27.5/20.0 | Tokyo 172 | 40/80 | No/No |
LOE Level of evidence, RCT Randomized-controlled trial, R Retrospective, NMIBC Non-muscle-invasive bladder cancer, BCa Bladder cancer, Case/Control, Low-dose/Standard-dose BCG.
* Mean or median.
** Maintenance is defined as any instillation beyond the induction course.